S-100beta protein--serum levels in children with brain neoplasms and its potential as a tumor marker.

Publication/Presentation Date

5-1-2004

Abstract

OBJECTIVE: To determine if serum S-100beta levels are elevated in children with brain neoplasms and if it can be used as a tumor marker for children with brain neoplasms.

DESIGN: Prospective cohort study.

SETTING: Urban, tertiary care, children's teaching hospital.

PATIENTS: 136 healthy children and 27 children with brain neoplasms.

METHODS: Serum levels of S-100beta were measured in 136 healthy children to serve as controls and 27 children with brain neoplasms, who underwent biopsy or resection of the mass. Patients were then classified into astrocytoma or non-astrocytoma groups.

MEASUREMENTS AND MAIN RESULTS: The median serum S-100beta level for the control group was 0.27 mcg/l (range, 0.06-2.6 mcg/l), and for the brain neoplasm group was 0.2 mcg/l (range, 0.01-2.1 mcg/l), (p = 0.09). There were 13 children with astrocytomas and 14 with non-astrocytomas. The S-100beta levels for the astrocytoma group was 0.25 mcg/l (range, 0.05-1.1 mcg/l) and for the non-astrocytoma group 0.17 mcg/l (range, 0.01-2.1 mcg/l), (p = 0.47).

CONCLUSIONS: Serum S-100beta levels are not elevated in children with brain neoplasms compared to healthy children, nor are they elevated in children with astrocytomas compared to non-astrocytomas. The S-100beta protein does not appear to be useful as a serum tumor marker in children with brain neoplasms.

Volume

67

Issue

3

First Page

345

Last Page

349

ISSN

0167-594X

Disciplines

Medicine and Health Sciences | Pediatrics

PubMedID

15164991

Department(s)

Department of Pediatrics

Document Type

Article

Link to Full Text

Share

COinS